|
|
|
|
To determine whether neutralizing antibodies (NABs) to interferon beta (INFB)-1a (Avonex) and IFNB-1b (Betaseron) cross-react. NABs to INFB-1a (Avonex) and IFNB-1b (Betaseron) cross-react, both in the binding and the biologic assays. This suggests that switching to alternate IFNB preparation in patients who develop NABs may not be clinically beneficial. Studies examining cross-reactivity between NABs to IFNB-1a and IFNB-1b in a large number of patients are indicated. |
|